CIK 0000914475
- Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330525145
- Phone
- +1 858-617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-31 | ABERNETHY MATT Chief Financial Officer | Grant or award · Stock Option | +66,362 | 66,362 | ||
| 2022-01-31 | ABERNETHY MATT Chief Financial Officer | Grant or award · Restricted Stock Unit | +9,745 | 9,745 | ||
| 2022-01-31 | ROBERTS EIRY Chief Medical Officer | Grant or award · Stock Option | +75,411 | 75,411 | ||
| 2022-01-31 | ROBERTS EIRY Chief Medical Officer | Grant or award · Restricted Stock Unit | +11,074 | 11,074 | ||
| 2022-01-31 | GORMAN KEVIN CHARLES Chief Executive Officer | Grant or award · Stock Option | +140,049 | 140,049 | ||
| 2022-01-31 | GORMAN KEVIN CHARLES Chief Executive Officer | Grant or award · Restricted Stock Unit | +20,565 | 20,565 | ||
| 2022-01-24 | SHERWIN STEPHEN A Director | Option exercise | +15,000 | $6.66 | $100K | 40,055 |
| 2022-01-24 | SHERWIN STEPHEN A Director | Sale | −15,000 | $74.43 | $1.1M | 25,055 |
| 2022-01-24 | SHERWIN STEPHEN A Director | Option exercise · Non-Qualified Stock Option | −15,000 | $6.66 | $100K | 0 |
| 2022-01-10 | ROBERTS EIRY Chief Medical Officer | Sale | −2,632 | $74.50 | $196K | 21,279 |
| 2022-01-05 | Gano Kyle Chief Business Development Off | Option exercise | +28,266 | $8.66 | $245K | 133,250 |
| 2022-01-05 | Gano Kyle Chief Business Development Off | Sale | −28,266 | $85.50 | $2.4M | 104,984 |
| 2022-01-05 | Gano Kyle Chief Business Development Off | Option exercise · Non-Qualified Stock Option | −28,266 | $8.66 | $245K | 0 |
| 2021-12-14 | SHERWIN STEPHEN A Director | Gift | −2,000 | 25,055 | ||
| 2021-12-10 | Lippoldt Darin Chief Legal Officer | Gift | −120 | 34,448 | ||
| 2021-12-01 | ABERNETHY MATT Chief Financial Officer | Sale | −1,645 | $82.59 | $136K | 16,349 |
| 2021-11-29 | Onyia Jude Chief Scientific Officer | Grant or award · Stock Option | +120,169 | 120,169 | ||
| 2021-11-29 | Onyia Jude Chief Scientific Officer | Grant or award · Restricted Stock Unit | +17,702 | 17,702 | ||
| 2021-10-07 | LYONS GARY A Director | Sale | −5,000 | $105.06 | $525K | 208,697 |
| 2021-10-07 | Grigoriadis Dimitri E. Chief Research Officer | Sale | −3,000 | $104.75 | $314K | 82,273 |
Page 57 of 62 · 1,221 trades